Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GBS-NN/NN2 Vaccine in Elderly Participants
NCT05782179Phase 1Completed
- Sponsor
- MinervaX
- Start
- Mar 2023
- Primary completion
- Dec 2023
- Modality
- Recombinant Proteins and Enzymes, Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of GBS-NN/NN2 vaccine in group B streptococcal infection (8 cohorts), sponsored by MinervaX. Primary endpoint: Safety and Tolerability of the GBS-NN/NN2 Vaccine. Started Mar 2023; status: completed.
02
Drugs
GBS-NN/NN2 vaccine
03
Conditions
group B streptococcal infection
Beyond the preview
Go deeper on NCT05782179.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05782179.